摘要
法舒地尔是目前唯一临床可用的Rho激酶抑制剂暨新型细胞内Ca2+拮抗剂,能强效扩血管、保护缺血脑组织,临床主要用于蛛网膜下腔出血手术后脑血管痉挛、脑缺血等的防治。鉴于Rho蛋白／Rho激酶系统在细胞分子水平生命活动中的重要意义,近年来,对法舒地尔的研究不断深入,其脑、心血管系统保护作用尤其明了。该药更多的适应证已处于临床试验后期中,有望成为颇具前景的新型脑、心血管活性药物。
Fasudil, the only Rho-kinase inhibitor available in clinical and a novel intracellular calcium antagonist, can increase regional blood flow and protect brain tissue, is mainly used to prevent cerebral vasospasm, cerabral ischemia, etc. after the surgery for subarachnoid hemorrhage. The system of Rho/Rho kinases is important in life activities. With the progress of the research, the molecular mechanism for the regulation of Rho-kinase by fasudil becomes clear. Fasudil is in terminal clinical trials for more applications and is prospect in the treatment of cardio-cerebral vascular diseases.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2006年第12期941-945,共5页
Chinese Journal of New Drugs and Clinical Remedies
关键词
法舒地尔
蛋白激酶抑制剂
钙通道阻滞药
脑
心血管系统
fasudil
protein kinase inhibitors
calcium channel blockers
brain
cardiovascular system
